Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
29.03
-0.80 (-2.68%)
At close: Jun 27, 2025, 4:00 PM
28.99
-0.04 (-0.14%)
After-hours: Jun 27, 2025, 7:20 PM EDT
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 14 analysts that cover Avidity Biosciences stock have a consensus rating of "Strong Buy" and an average price target of $68, which forecasts a 134.24% increase in the stock price over the next year. The lowest target is $53 and the highest is $96.
Price Target: $68 (+134.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Avidity Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Buy | 4 | 4 | 6 | 6 | 6 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 12 | 12 | 12 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $96 | Buy | Reiterates | $96 | +230.69% | Jun 27, 2025 |
| Wolfe Research | Wolfe Research | Buy Initiates $55 | Buy | Initiates | $55 | +89.46% | Jun 17, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +123.91% | Jun 11, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $70 → $75 | Strong Buy | Maintains | $70 → $75 | +158.35% | Jun 10, 2025 |
| Barclays | Barclays | Buy Maintains $57 → $59 | Buy | Maintains | $57 → $59 | +103.24% | Jun 10, 2025 |
Financial Forecast
Revenue This Year
6.35M
from 10.90M
Decreased by -41.73%
Revenue Next Year
16.31M
from 6.35M
Increased by 156.80%
EPS This Year
-4.07
from -2.89
EPS Next Year
-4.58
from -4.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 13.8M | 81.6M | 770.0M |
| Avg | 6.4M | 16.3M | 332.4M |
| Low | n/a | n/a | 74.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 27.0% | 1,184.8% | 4,621.7% |
| Avg | -41.7% | 156.8% | 1,938.1% |
| Low | - | - | 356.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.85 | -2.78 | -0.38 |
| Avg | -4.07 | -4.58 | -2.82 |
| Low | -5.25 | -5.53 | -4.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.